Navigation Links
Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
Date:7/12/2011

BETHLEHEM, Pa., July 12, 2011 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption Systems, a leading provider of pre-clinical pharmacokinetic services, announced today that the two companies are working together to provide their clients with enhanced drug development services by integrating pre-clinical pharmacokinetic data into the dosage form development scheme.  

According to Robert Lee, Ph.D., Particle Sciences' Vice President Pharmaceutical Development, "Particle Sciences has always had a methodical approach to drug product development.  Dosage form design is best done when informed by the in vivo solubility, permeability and metabolism of the drug.  This is true for oral drug products as well as other routes of administration.  Absorption Systems has put in place a scaled in vitro / ex vivo / in vivo approach to obtaining this data, which lends itself to our needs.  For those clients that desire it, Particle Sciences can integrate this data stream into our drug product development plan.  Ultimately, this should prove to be a cost-effective way to drive efficiency and minimize time to the clinic."

Chris Bode, Ph.D., Vice President Scientific & Corporate Communications at Absorption Systems, adds that "Our portfolio includes a number of physicochemical and biological tests that can make formulation development a more rational and efficient process.  Particle Sciences is a leader in drug formulation and manufacturing, and we are very pleased that they are leveraging our toolset in their efforts.  I believe this is consistent with their overall innovative and comprehensive approach to drug product development".

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices.  The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment.  Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world.  For information on the company's comprehensive contract services and applied research programs, please visit www.absorption.com.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery.  Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Mattera Cochran
1-610-861-4701
mcochran@particlesciences.com


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
6. Particle Sciences Expands Its Combination Product Capabilities
7. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
8. Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities
9. MicroConstants Now Offers Nanoparticle Formulation Services
10. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
11. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... from its market value in 2016. There are currently three proton therapy ... capacity to treat more patients. In Italy , the ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
Breaking Medicine Technology:
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... Dr. ... on early orthodontic treatment and accepting new pediatric patients, with or without a referral. ... young patients have a better orthodontic outcome and experience. When patients receive early treatment, ...
(Date:3/29/2017)... MINNETONKA, Minn. (PRWEB) , ... March 29, 2017 ... ... of medical office buildings (MOBs) and other outpatient facilities, and who are the ... look exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , ... announce the finalization of the company’s executive management team with prominent executives from both ... is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
Breaking Medicine News(10 mins):